#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neovascular age-related macular degeneration Ichthyosis Mitochondrial encephalomyopathy Retinitis pigmentosa Ovarian epithelial cancer Congenital myopathy Microscopic polyangiitis Methylmalonic acidaemia Cardiac failure acute B-cell small lymphocytic lymphoma recurrent Glomerulonephritis Myeloproliferative neoplasm Hypersensitivity pneumonitis Burkitt's lymphoma refractory Pneumonia More trials…

    Learn about Rare Diseases

    Nodal marginal zone B-cell lymphoma – Basic Information Primary hyperoxaluria – Trials in Disease Hairy cell leukaemia – Diagnostics MELAS syndrome – Treatment Mantle cell lymphoma stage II Hereditary motor and sensory neuropathy – Diagnostics Lymphangioma – Treatment Netherton’s syndrome – Basic Information Progressive multifocal leukoencephalopathy – Life with Disease Adrenogenital syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Darunavir Vedolizumab Rbl012.2 Eptacog Alfa (Activated) NADOFARAGENE FIRADENOVEC Obefazimod Acenocoumarol Triamcinolone Hexacetonide Emrusolmin Dazucorilant Nvl-655 Galcanezumab Glutathione Coffee Charcoal Ertugliflozin Diclofenac Diethylamine Tucidinostat Avb-101 Apitegromab Bortezomib More therapies…

    Learn about Your Condition

    Neurodegenerative disorder Mechanical ventilation Diabetic neuropathy Alcohol abuse Colitis ulcerative Corneal graft rejection Cardiac ventricular thrombosis Peritoneal neoplasm Ewing's sarcoma Retinitis pigmentosa Hepatocellular carcinoma Upper limb fracture Haemoptysis Macular telangiectasia Mitochondrial myopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Eczema
    • Dermatitis atopic
    Investigated Drugs:
    • Liquid Paraffin
    • Methylprednisolone Aceponate
    • Paraffin White Soft
    Germany Sweden

  • Study on Dupilumab Step-Down Strategy for Maintaining Remission in Adults and Adolescents with Atopic Dermatitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Betamethasone Valerate
    • Clobetasol
    • Desonide
    France

  • Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Germany Poland

  • Study on the Effectiveness and Safety of BP1.7881 for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Bp1.7881A
    France Germany Poland

  • Study on Reducing Dupilumab Dose for Patients with Controlled Atopic Eczema

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Dupilumab
    The Netherlands

  • Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Eczema
    • Dermatitis atopic
    Investigated Drugs:
    • Agents For Dermatitis, Excluding Corticosteroids
    • Corticosteroids, Potent (Group Iii)
    • Corticosteroids, Very Potent (Group Iv)
    Czechia France Germany Poland Spain
Previous Page
1 … 11 12 13 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!